Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of Tuesday, October 6, 2026.
RETURN ON EQUITY (ROE)
N/A
Latigo Biotherapeutics Inc.
Market Cap
$1.00B
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$986.50M
Return on Equity (ROE)
-25.78%
TTM Avg
29.18%
3Y Avg
31.59%
5Y Avg
31.59%
Market Cap
$990.37M
Return on Equity (ROE)
-32.27%
TTM Avg
-24.43%
3Y Avg
-32.70%
5Y Avg
-40.03%
Market Cap
$979.84M
Return on Equity (ROE)
36.64%
TTM Avg
876.73%
3Y Avg
395.64%
5Y Avg
252.56%
Market Cap
$984.09M
Return on Equity (ROE)
2.18%
TTM Avg
-5.89%
3Y Avg
-1.23%
5Y Avg
4.05%
Market Cap
$980.51M
Return on Equity (ROE)
-15.09%
TTM Avg
46.85%
3Y Avg
62.20%
5Y Avg
62.20%
Market Cap
$1.03B
Return on Equity (ROE)
-4.51%
TTM Avg
-33.13%
3Y Avg
-42.62%
5Y Avg
-42.62%
Market Cap
$1.03B
Return on Equity (ROE)
-52.47%
TTM Avg
-18.98%
3Y Avg
-16.96%
5Y Avg
-116.25%
Market Cap
$1.04B
Return on Equity (ROE)
-0.69%
TTM Avg
-24.98%
3Y Avg
-8.92%
5Y Avg
-2.80%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Latigo Biotherapeutics Inc. (LTGO) | $1.00B | N/A | N/A | N/A | N/A |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $986.50M | -25.78% | 29.18% | 31.59% | 31.59% |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $990.37M | -32.27% | -24.43% | -32.70% | -40.03% |
| MeiraGTx Holdings plc (MGTX)vs › | $979.84M | 36.64% | 876.73% | 395.64% | 252.56% |
| Pacira BioSciences, Inc. (PCRX)vs › | $984.09M | 2.18% | -5.89% | -1.23% | 4.05% |
| Aktis Oncology, Inc. (AKTS)vs › | $980.51M | -15.09% | 46.85% | 62.20% | 62.20% |
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI)vs › | $1.03B | -4.51% | -33.13% | -42.62% | -42.62% |
| Immatics N.V. (IMTX)vs › | $1.03B | -52.47% | -18.98% | -16.96% | -116.25% |
| Integra LifeSciences Holdings Corporation (IART)vs › | $1.04B | -0.69% | -24.98% | -8.92% | -2.80% |
| Janux Therapeutics, Inc. (JANX)vs › | $1.03B | -11.06% | -9.32% | -13.81% | -2.96% |
ROE
N/A
ROA
N/A
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
